This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Henry Schein (HSIC) Down 1.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC), led by the strength of its dental business.
Here's Why Henry Schein (HSIC) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Henry Schein (HSIC) Q2 Earnings Top, Operating Margin Dips
by Zacks Equity Research
Henry Schein's (HSIC) second quarter 2023 performance demonstrates strength in the North American dental business.
Compared to Estimates, Henry Schein (HSIC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Henry Schein (HSIC) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Henry Schein (HSIC) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 4.80% and 0.38%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
3 MedTech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.
Staar Surgical (STAA) Q2 Earnings Beat Estimates
by Zacks Equity Research
Staar Surgical (STAA) delivered earnings and revenue surprises of 25% and 0.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will High Medical Costs Hurt Cigna (CI) in Q2 Earnings?
by Zacks Equity Research
Cigna's (CI) Q2 results are likely to reflect strength in the specialty pharmacy business and growing medical customer base, partly offset by higher medical expenses.
Henry Schein (HSIC) Set to Post Q2 Earnings: What Awaits?
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter 2023 results are likely to be aided by the Dental business and new buyouts.
Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Conmed (CNMD) delivered earnings and revenue surprises of 5.06% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
What's in the Cards for Universal Health (UHS) in Q2 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q2 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.
Henry Schein (HSIC) Stock Moves -0.78%: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed at $78.81 in the latest trading session, marking a -0.78% move from the prior day.
Henry Schein (HSIC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Henry Schein (HSIC) closed at $81.10, marking a +0.25% move from the previous day.
Henry Schein (HSIC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed the most recent trading day at $80.90, moving +1.2% from the previous trading session.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.
Henry Schein (HSIC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Henry Schein (HSIC) closed at $78.90, marking a -1.02% move from the previous day.
Henry Schein (HSIC) Stock Moves -0.17%: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed the most recent trading day at $77.89, moving -0.17% from the previous trading session.
Henry Schein (HSIC) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed at $76.01 in the latest trading session, marking a +0.62% move from the prior day.
Why Is Henry Schein (HSIC) Down 1.3% Since Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein (HSIC) Stock Moves -0.15%: What You Should Know
by Zacks Equity Research
Henry Schein (HSIC) closed the most recent trading day at $75.26, moving -0.15% from the previous trading session.
Here's Why Investors Should Retain Henry Schein (HSIC) for Now
by Zacks Equity Research
Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.
Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.